Lilly prevails in long-running French Alimta patent dispute

16 September 2020

US pharma major Eli Lilly (NYSE: LLY) has secured a major win in its long-running patent dispute with Fresenius Kabi over Alimta (pemetrexed for injection), a lung cancer drug that generated global sales of around $2.13 billion in 2019.

In France, the Paris Court of First Instance handed down its judgment on the merits in the case, ruling that the firm’s generic version of pemetrexed disodium infringes on Eli Lilly’s European patent in France (EP 1 313 508).

After summer successes at the German Federal Court of Justice and the Supreme Court of the Netherlands over its pemetrexed, Lilly has achieved an important victory in France, and secured exclusivity to the French market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK